These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31103132)

  • 21. Comparison of Durable-Polymer- and Biodegradable-Polymer-Based Newer-Generation Drug-Eluting Stents in Patients with Acute Myocardial Infarction and Prediabetes After Successful Percutaneous Coronary Intervention.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Int Heart J; 2020 Jul; 61(4):673-684. PubMed ID: 32684595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: a randomized Long Drug-Eluting Stent V trial.
    Lee JY; Park DW; Kim YH; Ahn JM; Kim WJ; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Yang TH; Lee BK; Lee NH; Yang JY; Shin WY; Park HS; Kim KS; Hur SH; Lee SY; Park JS; Choi YS; Lee SU; Her SH; Park SJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):322-9. PubMed ID: 24823426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial.
    Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Puricel S; Slagboom T; Goy JJ; den Heijer P; van der Ent M
    EuroIntervention; 2015 Jul; 11(3):272-9. PubMed ID: 26196753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial.
    Natsuaki M; Kozuma K; Morimoto T; Kadota K; Muramatsu T; Nakagawa Y; Akasaka T; Igarashi K; Tanabe K; Morino Y; Ishikawa T; Nishikawa H; Awata M; Abe M; Okada H; Takatsu Y; Ogata N; Kimura K; Urasawa K; Tarutani Y; Shiode N; Kimura T;
    J Am Coll Cardiol; 2013 Jul; 62(3):181-190. PubMed ID: 23684673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients: a prospective non-randomized single-centre long-term comparison.
    Sprimont P; Pierard S; Vanoverschelde JL; Debbas N
    Acta Cardiol; 2014 Oct; 69(5):523-31. PubMed ID: 25638840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two-year clinical outcomes of the NOBORI biolimus-eluting stents versus XIENCE/PROMUS everolimus-eluting stents in small vessel disease.
    Jinnouchi H; Kuramitsu S; Shinozaki T; Hiromasa T; Kobayashi Y; Morinaga T; Yamaji K; Soga Y; Shirai S; Ando K
    Catheter Cardiovasc Interv; 2016 Nov; 88(5):E132-E138. PubMed ID: 26708085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymer-free amphilimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus.
    Godino C; Pivato CA; Chiarito M; Donahue M; Testa L; Colantonio R; Cappelletti A; Milazzo D; Parisi R; Nicolino A; Moshiri S; Aprigliano G; Palloshi A; Zavalloni Parenti D; Rutigliano D; Locuratolo N; Melillo F; Scotti A; Arrigoni L; Montorfano M; Fattori R; Presbitero P; Sardella G; Bedogni F; Margonato A; Briguori C; Colombo A;
    Int J Cardiol; 2017 Oct; 245():69-76. PubMed ID: 28874301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents.
    Kandzari DE; Koolen JJ; Doros G; Massaro JJ; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    J Am Coll Cardiol; 2018 Dec; 72(25):3287-3297. PubMed ID: 30257191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
    Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
    EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term comparison of everolimus-eluting and biolimus-eluting stents.
    Puricel S; Oberhänsli M; Guntern P; Lehmann S; Goy JJ; Arroyo D; Villeneuve H; Baeriswyl G; Stauffer JC; Togni M; Cook S
    EuroIntervention; 2013 Jul; 9(3):336-44. PubMed ID: 23482296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial).
    Patel KP; Lansky AJ; Kelbæk H; Xu B; van Royen N; Johnson TW; Anderson R; Wijns W; Baumbach A;
    Am J Cardiol; 2024 Apr; 217():94-101. PubMed ID: 38350507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twelve-month comparative analysis of clinical outcomes using biodegradable polymer-coated everolimus-eluting stents versus durable polymer-coated everolimus-eluting stents in all-comer patients.
    Abhyankar A; Sandhu MS; Polavarapu RS
    Indian Heart J; 2019; 71(2):149-154. PubMed ID: 31280828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
    Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
    JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
    Pilgrim T; Heg D; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Fahrni T; Moschovitis A; Noble S; Eberli FR; Wenaweser P; Jüni P; Windecker S
    Lancet; 2014 Dec; 384(9960):2111-22. PubMed ID: 25189359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies).
    Lansky AJ; Kastrati A; Edelman ER; Parise H; Ng VG; Ormiston J; Wijns W; Byrne RA
    Am J Cardiol; 2016 Feb; 117(4):532-538. PubMed ID: 26762729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biodegradable or durable polymer drug-eluting stents in patients with coronary artery disease: ten-year outcomes of the randomised NEXT Trial.
    Natsuaki M; Watanabe H; Morimoto T; Kozuma K; Kadota K; Muramatsu T; Nakagawa Y; Akasaka T; Hanaoka KI; Tanabe K; Morino Y; Ishikawa T; Katoh H; Nishikawa H; Tamura T; Ono K; Yamamoto K; Ishihara T; Abe M; Taniguchi R; Ikari Y; Okada K; Kimura T
    EuroIntervention; 2023 Aug; 19(5):e402-e413. PubMed ID: 37395475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
    J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.